Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Psychiatry
•
General Outpatient Psychiatry
•
Psychotic Disorders
•
Psychopharmacology
How do you approach deprescribing anticholinergics in patients with psychotic disorders?
Related Questions
How do you monitor patients who are symptomatically well-managed on clozapine with supratherapeutic drug levels?
How do you approach titration or transitioning to Cobenfy in patients currently on an antipsychotic?
How would you decide between escalation to clozapine vs xanomeline-tropsium (Cobenfy) for treatment-resistant schizophrenia?
How will the removal of the clozapine REMS requirement change your clinical practice?
When do you consider using Uzedy, the subcutaneous long-acting injectable version of risperidone?
When do you consider using olanzapine/samidorphan?
What is your approach to using newer atypical antipsychotics in the treatment of schizophrenia?
How do you approach liver function testing and monitoring when using xanomeline/tropsium (Cobenfy)?
What opportunities do you see for combining xanomeline-tropsium (Cobenfy) with other anti-psychotic agents?
Which patients do you think would benefit most from xanomeline-tropsium (Cobenfy) monotherapy?
